ImmunityBio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IBRX, updated each market day.
IBRX AI Sentiment
AI sees no strong directional signal for ImmunityBio, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About ImmunityBio, Inc. Common Stock
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Sector
Exchange
Market Cap
$8,966,214,869
Cap Tier
Employees
691
Headquarters
SAN DIEGO, CA
Listed Since
March 10, 2021
Website
IBRX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IBRX Volatility
ImmunityBio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
